Does Ethnicity Matter in Multiple Myeloma Risk Prediction in the Era of Genomics and Novel Agents? Evidence From Real-World Data

被引:7
作者
Farswan, Akanksha [1 ]
Gupta, Anubha [1 ]
Sriram, Krishnamachari [2 ]
Sharma, Atul [3 ]
Kumar, Lalit [3 ]
Gupta, Ritu [4 ]
机构
[1] Indraprastha Inst Informat Technol Delhi, Dept Elect & Commun, Signal Proc & Biomed Imaging Lab SBILab, New Delhi, India
[2] Indraprastha Inst Informat Technol Delhi, Dept Computat Biol, New Delhi, India
[3] AIIMS, Dr BRA IRCH, Dept Med Oncol, New Delhi, India
[4] All India Inst Med Sci Dr BRA IRCH, AIIMS, Rotary Canc Hosp, Dr Bhim Rao Ambedkar Inst,Lab Oncol Unit, New Delhi, India
关键词
AI in cancer research; ML in cancer survival; risk stratification of multiple myeloma; GMM clustering in cancer; consensus clustering in cancer; hematological malignancy; INTERNATIONAL STAGING SYSTEM; GENE-EXPRESSION DATA; DISPARITIES; CANCER; IMPUTATION; SURVIVAL;
D O I
10.3389/fonc.2021.720932
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IntroductionCurrent risk predictors of multiple myeloma do not integrate ethnicity-specific information. However, the impact of ethnicity on disease biology cannot be overlooked. In this study, we have investigated the impact of ethnicity in multiple myeloma risk prediction. In addition, an efficient and robust artificial intelligence (AI)-enabled risk-stratification system is developed for newly diagnosed multiple myeloma (NDMM) patients that utilizes ethnicity-specific cutoffs of key prognostic parameters. MethodsK-adaptive partitioning is used to propose new cutoffs of parameters for two different datasets-the MMIn (MM Indian dataset) dataset and the MMRF (Multiple Myeloma Research Foundation) dataset belonging to two different ethnicities. The Consensus-based Risk-Stratification System (CRSS) is designed using the Gaussian mixture model (GMM) and agglomerative clustering. CRSS is validated via Cox hazard proportional methods, Kaplan-Meier analysis, and log-rank tests on progression-free survival (PFS) and overall survival (OS). SHAP (SHapley Additive exPlanations) is utilized to establish the biological relevance of the risk prediction by CRSS. ResultsThere is a significant variation in the key prognostic parameters of the two datasets belonging to two different ethnicities. CRSS demonstrates superior performance as compared with the R-ISS in terms of C-index and hazard ratios on both the MMIn and MMRF datasets. An online calculator has been built that can predict the risk stage of a multiple myeloma (MM) patient based on the values of parameters and ethnicity. ConclusionOur methodology discovers changes in the cutoffs with ethnicities from the established cutoffs of prognostic features. The best predictor model for both cohorts was obtained with the new ethnicity-specific cutoffs of clinical parameters. Our study also revealed the efficacy of AI in building a deployable risk prediction system for MM. In the future, it is suggested to use the CRSS risk calculator on a large dataset as the cohort size of the present study is 25% of the cohort used in the R-ISS reported in 2015.
引用
收藏
页数:14
相关论文
共 29 条
[1]   Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups [J].
Ailawadhi, Sikander ;
Aldoss, Ibrahim T. ;
Yang, Dongyun ;
Razavi, Pedram ;
Cozen, Wendy ;
Sher, Taimur ;
Chanan-Khan, Asher .
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (01) :91-98
[2]   Multiple myeloma: A review of the epidemiologic literature [J].
Alexander, Dominik D. ;
Mink, Pamela J. ;
Adami, Hans-Olov ;
Cole, Philip ;
Mandel, Jack S. ;
Oken, Martin M. ;
Trichopoulos, Dimitrios .
INTERNATIONAL JOURNAL OF CANCER, 2007, :40-61
[3]   Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p) [J].
Avet-Loiseau, Herve ;
Leleu, Xavier ;
Roussel, Murielle ;
Moreau, Philippe ;
Guerin-Charbonnel, Catherine ;
Caillot, Denis ;
Marit, Gerald ;
Benboubker, Lotfi ;
Voillat, Laurent ;
Mathiot, Claire ;
Kolb, Brigitte ;
Macro, Margaret ;
Campion, Loic ;
Wetterwald, Marc ;
Stoppa, Anne-Marie ;
Hulin, Cyrille ;
Facon, Thierry ;
Attal, Michel ;
Minvielle, Stephane ;
Harousseau, Jean-Luc .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) :4630-4634
[4]   Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States [J].
Costa, Luciano J. ;
Brill, Ilene K. ;
Omel, James ;
Godby, Kelly ;
Kumar, Shaji K. ;
Brown, Elizabeth E. .
BLOOD ADVANCES, 2017, 1 (04) :282-287
[5]   Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis [J].
Derman, Benjamin A. ;
Jasielec, Jagoda ;
Langerman, Spencer S. ;
Zhang, Wei ;
Jakubowiak, Andrzej J. ;
Chiu, Brian C-H .
BLOOD CANCER JOURNAL, 2020, 10 (08)
[6]  
DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO
[7]  
2-U
[8]  
Eo SH, 2013, ARXIV PREPRINT ARXIV
[9]   AI-supported modified risk staging for multiple myeloma cancer useful in real-world scenario [J].
Farswan, Akanksha ;
Gupta, Anubha ;
Gupta, Ritu ;
Hazra, Saswati ;
Khan, Sadaf ;
Kumar, Lalit ;
Sharma, Atul .
TRANSLATIONAL ONCOLOGY, 2021, 14 (09)
[10]   Imputation of Gene Expression Data in Blood Cancer and Its Significance in Inferring Biological Pathways [J].
Farswan, Akanksha ;
Gupta, Anubha ;
Gupta, Ritu ;
Kaur, Gurvinder .
FRONTIERS IN ONCOLOGY, 2020, 9